Protein Degradation & Targeting Undruggables Europe 2022

Facilitate successful clinical translation of PROTACs and Molecular Glues by expanding target classes and the ligase landscape through rational discovery & design paradigms beyond oncology

VIEW THE 2022 AGENDA
Congress Centre, Basel, Switzerland
11-12 October, 2022

“Very interesting topic with cutting edge science presented by both pharma and academia.”

Rossella Guidetti, Lilly

“A lot of data on PROTAC research has been disclosed at this event. And also, many leaders in PROTACs shared their experience and concerns about their development. Many start-up companies also delivered their progress. We are able to discuss future directions as well as difficulties with experts from both industry and the academic area and learned a lot.”

Yuqing Huang Suzhou, Kintor Pharmaceuticals

Why Attend

The field of protein degradation has accelerated, and substantial interest is owed to its promise to therapeutically degrade proteins proving intractable to classical small molecule inhibition.

As the field patiently waits for clinical trial readouts, some say we are entering the next era, beyond current targets and disease indications. Ongoing research efforts in academia and industry prepare us for the next wave of challenges that need to be overcome:

  • Building up the foundational knowledge in the molecular glue space through novel rational glue discovery and design approaches and innovative structural tools to model ternary interactions
  • Novel strategies towards defining and clinically demonstrating the most optimal target classes and boosting the current E3 ligase repertoire beyond CRBN- and VHL-based mechanisms
  • Innovative approaches towards improved drug-like properties showcasing optimized oral bioavailability and DMPK/ADMET profiles to bring us a step closer to optimized clinical translation
  • Case studies that investigate TPD opportunities outside the realm of oncology while addressing potentially disguised hurdles therein and acquired resistance mechanisms

The fourth annual Protein Degradation & Targeting Undruggables European Congress provides a unique opportunity to assess recent developments in the implementation of novel technologies to further discovery, design and subsequent development of TPD-based therapies while engaging with the most senior experts in industry and academia in the region.

Join us in contributing to this ongoing effort to push away from the foundational era exploring the full potential of targeted protein degradation
as a novel therapeutic option across diverse indications.

Previous Attendees Include

Audience Breakdown

2022 Speakers

 

Ingrid Wertz

Executive Director, Protein Homeostasis Center of Excellence
BMS

Ingrid Wertz

Executive Director, Protein Homeostasis Center of Excellence
BMS

Ingrid Wertz

Executive Director, Protein Homeostasis Center of Excellence
BMS
 

Danette Daniels, Ph.D.

VP, Protein Degrader Platform
Foghorn Therapeutics

Danette received her B.A. from Columbia University, Ph.D. in Biophysics from Yale University, and completed a postdoctoral fellowship at Stanford University School of Medicine studying Wnt signaling pathway.  She has been at Promega Corporation for 15 years and is currently an R&D Group Leader of Functional Proteomics.  She leads a team developing technologies and performing research to understand dynamic intracellular interactions within the focus areas of epigenetics, targeted protein degradation, and drug discovery.

Danette Daniels, Ph.D.

VP, Protein Degrader Platform
Foghorn Therapeutics

Danette Daniels, Ph.D.

VP, Protein Degrader Platform
Foghorn Therapeutics

Danette received her B.A. from Columbia University, Ph.D. in Biophysics from Yale University, and completed a postdoctoral fellowship at Stanford University School of Medicine studying Wnt signaling pathway.  She has been at Promega Corporation for 15 years and is currently an R&D Group Leader of Functional Proteomics.  She leads a team developing technologies and performing research to understand dynamic intracellular interactions within the focus areas of epigenetics, targeted protein degradation, and drug discovery.

 

Eric Fischer

Associate Professor
Dana-Farber Cancer Institute

Eric Fischer, Ph.D. is Assistant Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and a Principal Investigator in the Department of Cancer Biology at Dana-Farber Cancer Institute. His research focuses on understanding the complex mechanisms that underlie function and regulation of multi-component ubiquitin ligases and their role in disease. His work further focuses on new therapeutic approaches such as targeted protein degradation.

Eric Fischer

Associate Professor
Dana-Farber Cancer Institute

Eric Fischer

Associate Professor
Dana-Farber Cancer Institute

Eric Fischer, Ph.D. is Assistant Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and a Principal Investigator in the Department of Cancer Biology at Dana-Farber Cancer Institute. His research focuses on understanding the complex mechanisms that underlie function and regulation of multi-component ubiquitin ligases and their role in disease. His work further focuses on new therapeutic approaches such as targeted protein degradation. He co-directs the DFCI Center for Protein Degradation and has been recognized for his pioneering work on the structure of cereblon and the mechanism of action of thalidomide.

 

Adam Gilbert

Executive Director, Head of Design and Synthesis Sciences
Pfizer

My group supports several important medchem platforms for Pfizer: protein degradation, DNA-encoded library chemistry, large and small-scale compound purification and phenotypic screening deconvolution.  Scientists in my group specialize in design and synthetic medicinal chemistry, computational chemistry, purification science as well as molecular property analysis.

Adam Gilbert

Executive Director, Head of Design and Synthesis Sciences
Pfizer

Adam Gilbert

Executive Director, Head of Design and Synthesis Sciences
Pfizer

My group supports several important medchem platforms for Pfizer: protein degradation, DNA-encoded library chemistry, large and small-scale compound purification and phenotypic screening deconvolution.  Scientists in my group specialize in design and synthetic medicinal chemistry, computational chemistry, purification science as well as molecular property analysis.

 

Karen Miller

Senior Scientist
BioTheryX

Karen Miller

Senior Scientist
BioTheryX

Karen Miller

Senior Scientist
BioTheryX
 

Greg Hollingworth

Director, New Modalities & TPD Global Initiatives Co-Lead
Novartis

Greg Hollingworth

Director, New Modalities & TPD Global Initiatives Co-Lead
Novartis

Greg Hollingworth

Director, New Modalities & TPD Global Initiatives Co-Lead
Novartis
 

Jeff McKenna

Director
Novartis

Jeff McKenna

Director
Novartis

Jeff McKenna

Director
Novartis
 

Manfred Koegl

Director of Oncology Research
Boehringer Ingelheim

I am a director in Oncology Research at Boehringer Ingelheim in Vienna, working on the discovery and implementation of new therapeutic concepts in cancer. The main focus of my team are novel approaches for cancer cell targeting by small molecule drugs.

Manfred Koegl

Director of Oncology Research
Boehringer Ingelheim

Manfred Koegl

Director of Oncology Research
Boehringer Ingelheim

I am a director in Oncology Research at Boehringer Ingelheim in Vienna, working on the discovery and implementation of new therapeutic concepts in cancer. The main focus of my team are novel approaches for cancer cell targeting by small molecule drugs.

 

Stefan Knapp

Professor, Principal Investigator
Goethe University

Stefan Knapp

Professor, Principal Investigator
Goethe University

Stefan Knapp

Professor, Principal Investigator
Goethe University
 

Sara Pannilunghi

University of Geneva

Sara Pannilunghi

University of Geneva

Sara Pannilunghi

University of Geneva
 

Elizabeth Caine

Senior Research Scientist
Promega

Elizabeth Caine

Senior Research Scientist
Promega

Elizabeth Caine

Senior Research Scientist
Promega
 

Agnieszka Konopacka

Principal Scientist
GSK

Agnieszka Konopacka

Principal Scientist
GSK

Agnieszka Konopacka

Principal Scientist
GSK
 

Satpal Virdee

Professor, Chemical Biology
MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee

Satpal Virdee

Professor, Chemical Biology
MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee

Satpal Virdee

Professor, Chemical Biology
MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee
 

Mikolaj Slabicki

Group Leader, Senior Scientist
DFCI / Broad Institute

Mikolaj Slabicki

Group Leader, Senior Scientist
DFCI / Broad Institute

Mikolaj Slabicki

Group Leader, Senior Scientist
DFCI / Broad Institute
 

Tom Shepherd

Captor Therapeutics

Tom Shepherd

Captor Therapeutics

Tom Shepherd

Captor Therapeutics
 

Elmar Wolf

Professor
University of Wurzbug

Elmar Wolf

Professor
University of Wurzbug

Elmar Wolf

Professor
University of Wurzbug
 

Zuzanna Kozicka

PhD Candidate
Friedrich Miescher Institute for Biomedical Research

I am a PhD student in the laboratory of Nicolas Thomä at the Friedrich Miescher Institute in Basel, Switzerland. I have an avid interest in molecular glue degraders and, more generally, in understanding how changes in protein interactomes can be brought about by the binding of small molecules. Prior to joining the Thomä lab, I completed my studies at the University of Edinburgh and I undertook various research projects, including one in the laboratory of Alessio Ciulli at the University of Dundee that focussed on PROTAC ‘linkerology’.

Zuzanna Kozicka

PhD Candidate
Friedrich Miescher Institute for Biomedical Research

Zuzanna Kozicka

PhD Candidate
Friedrich Miescher Institute for Biomedical Research

I am a PhD student in the laboratory of Nicolas Thomä at the Friedrich Miescher Institute in Basel, Switzerland. I have an avid interest in molecular glue degraders and, more generally, in understanding how changes in protein interactomes can be brought about by the binding of small molecules. Prior to joining the Thomä lab, I completed my studies at the University of Edinburgh and I undertook various research projects, including one in the laboratory of Alessio Ciulli at the University of Dundee that focussed on PROTAC ‘linkerology’.

 

Lurong Pan

CEO
Ainnocence

Lurong Pan

CEO
Ainnocence

Lurong Pan

CEO
Ainnocence
 

Allan Jordan

Director, Oncology Drug Discovery
Sygnature Discovery

Allan Jordan

Director, Oncology Drug Discovery
Sygnature Discovery

Allan Jordan

Director, Oncology Drug Discovery
Sygnature Discovery
 

Martin Steger

Scientist MS-Based Proteomics
Max Planck Institute of Biochemistry

Martin Steger

Scientist MS-Based Proteomics
Max Planck Institute of Biochemistry

Martin Steger

Scientist MS-Based Proteomics
Max Planck Institute of Biochemistry
 

Matthieu Schapira

Professor, Principal Investigator
University of Toronto

Matthieu Schapira

Professor, Principal Investigator
University of Toronto

Matthieu Schapira

Professor, Principal Investigator
University of Toronto
 

Stephanie Voss

Director, Biochemistry & Biophysics
Oerth Bio

Stephanie Voss

Director, Biochemistry & Biophysics
Oerth Bio

Stephanie Voss

Director, Biochemistry & Biophysics
Oerth Bio
 

Hyunsun Jo

CEO
Pin Therapeutics

Hyunsun Jo

CEO
Pin Therapeutics

Hyunsun Jo

CEO
Pin Therapeutics
 

Ivan Dikic

Professor, Director
Goethe University

Ivan Dikic

Professor, Director
Goethe University

Ivan Dikic

Professor, Director
Goethe University
 

Felix Hausch

Professor
Technical University Darmstadt

Felix Hausch

Professor
Technical University Darmstadt

Felix Hausch

Professor
Technical University Darmstadt
 

Giulia Caron

Professor, Medicinal Chemistry
University of Turin

Giulia Caron

Professor, Medicinal Chemistry
University of Turin

Giulia Caron

Professor, Medicinal Chemistry
University of Turin
 

Yusuke Tominari

Chief Executive Officer/Chief Scientific Officer
FIMECS, Inc.

Yusuke Tominari is a CEO and CEO, and manages the entire projects and strategy of FIMECS, Inc. He curved out from Takeda pharmaceutical company limited with his colleagues and launched FIMECS in 2018. He started his career of medicinal chemist at Takeda in 2006 after getting a PhD at the University of Tokyo in Japan. Through his 12 years of pharmaceutical experience, he has been mainly working on immunology and oncology areas.

Yusuke Tominari

Chief Executive Officer/Chief Scientific Officer
FIMECS, Inc.

Yusuke Tominari

Chief Executive Officer/Chief Scientific Officer
FIMECS, Inc.

Yusuke Tominari is a CEO and CEO, and manages the entire projects and strategy of FIMECS, Inc. He curved out from Takeda pharmaceutical company limited with his colleagues and launched FIMECS in 2018. He started his career of medicinal chemist at Takeda in 2006 after getting a PhD at the University of Tokyo in Japan. Through his 12 years of pharmaceutical experience, he has been mainly working on immunology and oncology areas.

FIMECS, Inc. is a drug discovery biotech developing a new class of drugs based on targeted protein degradation therapeutics for currently ‘undruggable’ targets in immune-oncology and oncology areas.

Utilizing our drug discovery platform, RaPPIDSTM to internal and collaborative programs, we rapidly discover therapeutic candidates to induce the degradation of disease-relevant targeted proteins.

Most important mission is the providing life-saving medicines to patients all over the world.

 

Zachary Carpenter

Founder, CEO
VantAI

Zachary Carpenter

Founder, CEO
VantAI

Zachary Carpenter

Founder, CEO
VantAI
 

Elisabeth Hennes

Senior Scientist
Almirall

Elisabeth Hennes

Senior Scientist
Almirall

Elisabeth Hennes

Senior Scientist
Almirall
 

Carlotta Cecchini

PhD Candidate, Pharmaceutical Biochemistry/Chemistry
University of Geneva

Carlotta Cecchini

PhD Candidate, Pharmaceutical Biochemistry/Chemistry
University of Geneva

Carlotta Cecchini

PhD Candidate, Pharmaceutical Biochemistry/Chemistry
University of Geneva

The Agenda

The Protein Degradation & Targetting Undruggables 2022 Europe agenda is here!

Simply fill out the short form and access your copy immediately. 


DOWNLOAD THE 2022 AGENDA

What attendees say

2022 Partners

Gold Partner

Event Partners

Become a partner

Kisaco Research provides the platform where industry executives can network, learn and meet potential industry partners.

Far from the typical ‘meet-and-greet’ experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand.

Your partnership with Kisaco Research will offer you a strategic approach that is an extension and enhancement of your own marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets.

Find out more by calling us at +44 (0)20 3696 2920 or email Ryan Sanderson at [email protected] 

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:

Ticket price will increase in

Thursday, May 26, 2022 to Friday, July 8, 2022
Tier 1 - Academics
€899
Super Super Early Bird Ends Friday, 8 July 2022. Save €1000.
Must be a full time academic
2 day conference pass
Networking opportunities
To increase your brand presence, contact [email protected]
Thursday, May 26, 2022 to Friday, July 8, 2022
Tier 2 - Drug Developers
€1,499
Super Super Early Bird Ends Friday, 8 July 2022. Save €800.
Must have active degrader therapeutic pipeline and less than 10 years old
2 day conference pass
Networking opportunities
To increase your brand presence, contact [email protected]
Thursday, May 26, 2022 to Friday, July 8, 2022
Tier 3 - Industry
€2,099
Super Super Early Bird Ends Friday, 8 July 2022. Save €1500.
2 day conference pass
Networking opportunities
To increase your brand presence, contact [email protected]
Preparing registration...

Venue

Congress Center Basel

Congress Center Basel, MCH Messe Schweiz (Basel) A, CH-4005 Basel

Resources

Download Resource

highlights from previous years

Protein degradation Congress

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us